# Evaluation of ALT-2074 in Subjects With Type-2 Diabetes, Haptoglobin Type 2-2 Genotype and Coronary Artery Disease

> **NCT00491543** · PHASE2 · COMPLETED · sponsor: **Synvista Therapeutics, Inc** · enrollment: 66 (estimated)

## Conditions studied

- Diabetes
- Coronary Artery Disease

## Interventions

- **DRUG:** ALT-2074

## Key facts

- **NCT ID:** NCT00491543
- **Lead sponsor:** Synvista Therapeutics, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-06
- **Primary completion:** —
- **Final completion:** 2008-05
- **Target enrollment:** 66 (ESTIMATED)
- **Last updated:** 2008-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00491543

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00491543, "Evaluation of ALT-2074 in Subjects With Type-2 Diabetes, Haptoglobin Type 2-2 Genotype and Coronary Artery Disease". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT00491543. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*